Wanbangde Pharmaceutical Holding Group Co., Ltd. (SHE:002082)
China · Delayed Price · Currency is CNY 16.21
-0.85 (-4.98%)
May 20, 2026, 11:55 AM CST
SHE:002082 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,176 | 1,117 | 1,427 | 1,531 | 1,770 | 1,923 |
Other Revenue | - | - | 16.11 | 10.51 | 16.46 | 7.86 |
| 1,176 | 1,117 | 1,443 | 1,542 | 1,786 | 1,931 | |
Revenue Growth (YoY) | -11.50% | -22.59% | -6.39% | -13.69% | -7.47% | -85.91% |
Cost of Revenue | 679.83 | 726.95 | 847.18 | 918.18 | 852.57 | 999.27 |
Gross Profit | 496.6 | 390.38 | 596.19 | 623.76 | 933.85 | 931.33 |
Selling, General & Admin | 375.94 | 377.1 | 443.02 | 458.13 | 579.71 | 571.77 |
Research & Development | 57.86 | 59.16 | 59.87 | 53.98 | 59.1 | 76.2 |
Other Operating Expenses | 35.45 | 8.77 | 19.42 | 17.89 | 23.48 | 20.43 |
Operating Expenses | 469.26 | 445.04 | 521.42 | 553.57 | 701.27 | 720.65 |
Operating Income | 27.34 | -54.66 | 74.77 | 70.19 | 232.58 | 210.69 |
Interest Expense | - | - | -38.5 | -46.48 | -33.2 | -35.6 |
Interest & Investment Income | 0.04 | 0.31 | 18.97 | 5.19 | 10.75 | 235.76 |
Currency Exchange Gain (Loss) | - | - | -0.05 | -4.53 | -0.82 | -0.93 |
Other Non Operating Income (Expenses) | -76.37 | -102.16 | -1.84 | -1.41 | -0.74 | -1.27 |
EBT Excluding Unusual Items | -48.99 | -156.51 | 53.35 | 22.96 | 208.58 | 408.65 |
Impairment of Goodwill | - | - | - | - | -67.78 | -19.27 |
Gain (Loss) on Sale of Investments | 10.42 | 10.45 | 2.94 | -1.83 | -0.56 | -2.39 |
Gain (Loss) on Sale of Assets | 0.6 | 0.6 | 15.74 | 0.12 | -0.95 | -1.21 |
Asset Writedown | -16.05 | -13.77 | -21.75 | -2.88 | -22.5 | -28.09 |
Other Unusual Items | - | - | 8.68 | 11.56 | -16.66 | 3.46 |
Pretax Income | -54.02 | -159.23 | 58.95 | 29.93 | 100.13 | 361.14 |
Income Tax Expense | 28.45 | 12.67 | 13.71 | 3.6 | 26.43 | 199.98 |
Earnings From Continuing Operations | -82.47 | -171.9 | 45.25 | 26.33 | 73.71 | 161.16 |
Minority Interest in Earnings | 2.98 | 4.66 | 10.19 | 22.88 | 19.55 | 5.35 |
Net Income | -79.49 | -167.24 | 55.44 | 49.21 | 93.26 | 166.51 |
Net Income to Common | -79.49 | -167.24 | 55.44 | 49.21 | 93.26 | 166.51 |
Net Income Growth | - | - | 12.67% | -47.23% | -43.99% | -41.56% |
Shares Outstanding (Basic) | 618 | 619 | 616 | 615 | 622 | 617 |
Shares Outstanding (Diluted) | 618 | 619 | 616 | 615 | 622 | 617 |
Shares Change (YoY) | 0.69% | 0.55% | 0.15% | -1.06% | 0.82% | 1.73% |
EPS (Basic) | -0.13 | -0.27 | 0.09 | 0.08 | 0.15 | 0.27 |
EPS (Diluted) | -0.13 | -0.27 | 0.09 | 0.08 | 0.15 | 0.27 |
EPS Growth | - | - | 12.50% | -46.67% | -44.44% | -42.55% |
Free Cash Flow | 427.74 | 314.33 | 23.11 | -201.59 | -406.88 | -263.42 |
Free Cash Flow Per Share | 0.69 | 0.51 | 0.04 | -0.33 | -0.65 | -0.43 |
Dividend Per Share | - | - | - | 0.080 | 0.120 | - |
Dividend Growth | - | - | - | -33.33% | - | - |
Gross Margin | 42.21% | 34.94% | 41.30% | 40.45% | 52.28% | 48.24% |
Operating Margin | 2.32% | -4.89% | 5.18% | 4.55% | 13.02% | 10.91% |
Profit Margin | -6.76% | -14.97% | 3.84% | 3.19% | 5.22% | 8.63% |
Free Cash Flow Margin | 36.36% | 28.13% | 1.60% | -13.07% | -22.78% | -13.64% |
EBITDA | 140.88 | 55.3 | 170.42 | 163.98 | 337.3 | 305.12 |
EBITDA Margin | 11.97% | 4.95% | 11.81% | 10.63% | 18.88% | 15.80% |
D&A For EBITDA | 113.54 | 109.96 | 95.65 | 93.79 | 104.72 | 94.43 |
EBIT | 27.34 | -54.66 | 74.77 | 70.19 | 232.58 | 210.69 |
EBIT Margin | 2.32% | -4.89% | 5.18% | 4.55% | 13.02% | 10.91% |
Effective Tax Rate | - | - | 23.25% | 12.04% | 26.39% | 55.37% |
Revenue as Reported | - | - | 1,443 | 1,542 | 1,786 | 1,931 |
Advertising Expenses | - | - | 1.49 | 3.73 | 1.32 | 4.86 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.